Strolll Pioneers AR Therapy Trial for Parkinson’s

On World Parkinson’s Day, IW Capital is proud to celebrate a major milestone achieved by our portfolio company, Strolll [https://strolll.co/]. The company has announced the launch of the world’s first clinical trial of an augmented reality (AR) rehabilitation platform specifically designed for people living with Parkinson’s disease.

Conducted in collaboration with the York Trials Unit and the University of Leeds, and supported by the NIHR i4i programme, the trial will evaluate both the clinical and economic impact of Strolll’s Reality DTx® neurorehabilitation platform. Patient recruitment begins this May, marking the start of an important new chapter in Parkinson’s care.

Reality DTx® delivers high-dose, personalised therapy through lightweight AR glasses, allowing patients to engage in daily rehabilitation from the comfort of home. The technology aims to improve mobility, restore confidence, and enhance quality of life, while also reducing the burden on NHS services.

This pioneering trial represents a significant step forward in making advanced rehabilitation more accessible, effective, and patient-centric.

At IW Capital, we invest in companies that drive meaningful innovation – and Strolll exemplifies this mission. Its work is not only transforming how neurological rehabilitation is delivered but also making a real, lasting impact on patients’ lives.

We are proud to support Strolll as its team leads the way in digital therapeutics, and we look forward to seeing the results of this important clinical trial.